Search Within

Thoracic Oncology

Formats
  1. Meeting Abstract (1709)
  2. Journal Article (1439)
  3. Review (82)
  4. Editorial (58)
  5. Book Section (35)
  6. Guidelines (25)
  7. Conference Paper (21)
  8. Correspondence (10)
  9. Research Letter (7)
  10. Miscellaneous (6)
  11. Book Whole (2)
Groups
  1. Department of Medicine (3394)
  2. Solid Tumor Oncology Division (3394)
  3. GSK Faculty (1071)
  4. Department of Pathology and Laboratory Medicine (809)
  5. Center for Molecular Imaging and Biotechnology (CMIB) (662)
  6. Human Oncology and Pathogenesis Program (635)

More Groups

People
  1. Mark Kris (872)
  2. Alexander Drilon (637)
  3. Gregory Riely (605)
  4. Charles Rudin (495)
  5. Marc Ladanyi (418)
  6. Matthew Hellmann (412)

More People

Years
  1. 2025 (114)
  2. 2024 (271)
  3. 2023 (273)
  4. 2022 (337)
  5. 2021 (337)
  6. 2020 (258)

More Years

Publications
  1. Journal of Clinical Oncology (703)
  2. Journal of Thoracic Oncology (517)
  3. Annals of Oncology (278)
  4. Clinical Cancer Research (158)
  5. Cancer Research (128)
  6. International Journal of Radiation Oncology, Biology, Physics (89)

More Publications

Publishers
  1. American Society of Clinical Oncology (782)
  2. Elsevier Inc. (738)
  3. American Association for Cancer Research (386)
  4. Oxford University Press (352)
  5. Nature Publishing Group (156)
  6. Elsevier Science, Inc. (79)

More Publishers

Results (3394)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Optimizing PD-L1 as a biomarker of response with pembrolizumab (pembro; MK-3475) as first-line therapy for PD-L1-positive metastatic non-small cell lung cancer (NSCLC): Updated data from KEYNOTE-001
    Meeting Abstract

    Rizvi, N. A.; Garon, E. B.; Leighl, N.; Hellmann, M. D.; Patnaik, A.; Gandhi, L.; Eder, J. P.; Rangwala, R. A.; Lubiniecki, G.; Zhang, J.; more...
    Journal of Clinical Oncology (2015)

    Fulltext@MSK | Save
  • A phase 1 study of crizotinib and ganetespib (STA-9090) in ALK positive lung cancers
    Meeting Abstract

    Riely, G. J.; Yu, H. A.; Stephens, D.; Pietanza, M. C.; Smith-Marrone, S.; Fiore, J. J.; Goldstein, M.; Sima, C. S.; Kris, M. G.; Ginsberg, M. S.
    Journal of Clinical Oncology (2015)

    Fulltext@MSK | Save
  • Prospective molecular analysis of small cell lung cancer (SCLC) using next generation sequencing (NGS)
    Meeting Abstract

    Pietanza, M. C.; Won, H. H.; Rekhtman, N.; Wang, L.; Travis, W. D.; Krug, L. M.; Varghese, A. M.; Paik, P. K.; Riely, G. J.; Zakowski, M. F.; more...
    Journal of Clinical Oncology (2015)

    Fulltext@MSK | Save
  • STARTRK-1: Phase 1/2a study of entrectinib, an oral Pan-Trk, ROS1, and ALK inhibitor, in patients with advanced solid tumors with relevant molecular alterations
    Meeting Abstract

    Patel, M. R.; Bauer, T. M.; Liu, S. V.; Drilon, A. E.; Wheler, J. J.; Shaw, A. T.; Farago, A. F.; Ou, S. H. I.; Luo, D.; Yeh, L.; more...
    Journal of Clinical Oncology (2015)

    Fulltext@MSK | Save
  • Response to crizotinib and cabozantinib in stage IV lung adenocarcinoma patients with mutations that cause MET exon 14 skipping
    Meeting Abstract

    Paik, P. K.; Drilon, A. E.; Yu, H. A.; Krug, L. M.; Rekhtman, N.; Borsu, L.; Ginsberg, M. S.; Berger, M. F.; Ladanyi, M.; Rudin, C. M.
    Journal of Clinical Oncology (2015)

    Fulltext@MSK | Save
  • Preliminary results of TATTON, a multi-arm phase Ib trial of AZD9291 combined with MEDI4736, AZD6094 or selumetinib in EGFR-mutant lung cancer
    Meeting Abstract

    Oxnard, G. R.; Ramalingam, S. S.; Ahn, M. J.; Kim, S. W.; Yu, H. A.; Saka, H.; Horn, L.; Goto, K.; Ohe, Y.; Cantarini, M.; more...
    Journal of Clinical Oncology (2015)

    Fulltext@MSK | Save
  • Prognostic significance of a diagnosis of multiple lung cancers
    Meeting Abstract

    Naidoo, J.; Woo, K.; Sima, C. S.; Finley, D. J.; Travis, W. D.; Rusch, V. W.; Kris, M. G.; Zauderer, M. G.
    Journal of Clinical Oncology (2015)

    Fulltext@MSK | Save
  • Defining the immunologic phenotype of thymic epithelial tumors
    Meeting Abstract

    Naidoo, J.; Steele, K.; Sima, C. S.; Yuan, J. D.; Robbins, P. B.; Moreira, A. L.; Pietanza, M. C.; Wolchok, J. D.; Riely, G. J.; Rizvi, N. A.
    Journal of Clinical Oncology (2015)

    Fulltext@MSK | Save
  • Phase II trial of bortezomib in KRAS G12D mutant lung cancers
    Meeting Abstract

    Litvak, A. M.; Drilon, A. E.; Rekhtman, N.; Pietanza, M. C.; Chaft, J. E.; Woo, K.; Paik, P. K.; Kris, M. G.; Riely, G. J.
    Journal of Clinical Oncology (2015)

    Fulltext@MSK | Save
  • Defining the spectrum and "overlap" of HER2 aberrations in lung cancers: Associations of HER2 protein overexpression, HER2 amplification, and HER2 mutation
    Meeting Abstract

    Li, B. T.; Ross, D. S.; Chaft, J. E.; Hsu, M.; Kako, S.; Aisner, D. L.; Kris, M. G.; Varella-Garcia, M.; Arcila, M. E.
    Journal of Clinical Oncology (2015)

    Fulltext@MSK | Save